Prostate cancer is the second-leading cause of cancer-relateddeath among men and the seventh most common cause of death inthe United States overall. Most prostate cancers are androgen-dependent,meaning that they respond to androgen-ablation therapy. However,these tumors eventually become androgen-independent and growdespite androgen ablation. When prostate cancer is localizedin the prostate, the treatment of choice is prostatectomy orirradiation. However, when the tumor relapses or is alreadymetastatic at diagnosis, therapy is problematic. Androgen ablationhas been the main option for unconfined disease for more than50 years, since Clarence V. Hodges and Charles B. Huggins . . . [Full Text of this Article]
Source Information
From the Departments of Urology and Biochemistry and Molecular Biology, Mayo Clinic College of Medicine, Rochester, Minn.
This article has been cited by other articles:
Ai, J., Wang, Y., Dar, J. A., Liu, J., Liu, L., Nelson, J. B., Wang, Z.
(2009). HDAC6 Regulates Androgen Receptor Hypersensitivity and Nuclear Localization via Modulating Hsp90 Acetylation in Castration-Resistant Prostate Cancer. Mol. Endocrinol.
23: 1963-1972
[Abstract][Full Text]
Gan, L., Chen, S., Wang, Y., Watahiki, A., Bohrer, L., Sun, Z., Wang, Y., Huang, H.
(2009). Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer. Cancer Res.
69: 8386-8394
[Abstract][Full Text]
McDonald, R., White, J., Marmor, T. R.
(2009). Paying for Performance in Primary Medical Care: Learning about and Learning from "Success" and "Failure" in England and California. Journal of Health Politics, Policy and Law
34: 747-776
[Abstract]
Pu, H., Collazo, J., Jones, E., Gayheart, D., Sakamoto, S., Vogt, A., Mitchell, B., Kyprianou, N.
(2009). Dysfunctional Transforming Growth Factor-{beta} Receptor II Accelerates Prostate Tumorigenesis in the TRAMP Mouse Model. Cancer Res.
69: 7366-7374
[Abstract][Full Text]
Concato, J., Jain, D., Uchio, E., Risch, H., Li, W. W., Wells, C. K.
(2009). Molecular Markers and Death From Prostate Cancer. ANN INTERN MED
150: 595-603
[Abstract][Full Text]
Heemers, H. V., Regan, K. M., Schmidt, L. J., Anderson, S. K., Ballman, K. V., Tindall, D. J.
(2009). Androgen Modulation of Coregulator Expression in Prostate Cancer Cells. Mol. Endocrinol.
23: 572-583
[Abstract][Full Text]
Chen, L.-H., Fang, J., Sun, Z., Li, H., Wu, Y., Demark-Wahnefried, W., Lin, X.
(2009). Enterolactone Inhibits Insulin-Like Growth Factor-1 Receptor Signaling in Human Prostatic Carcinoma PC-3 Cells. J. Nutr.
139: 653-659
[Abstract][Full Text]
Guo, Z., Yang, X., Sun, F., Jiang, R., Linn, D. E., Chen, H., Chen, H., Kong, X., Melamed, J., Tepper, C. G., Kung, H.-J., Brodie, A. M.H., Edwards, J., Qiu, Y.
(2009). A Novel Androgen Receptor Splice Variant Is Up-regulated during Prostate Cancer Progression and Promotes Androgen Depletion-Resistant Growth. Cancer Res.
69: 2305-2313
[Abstract][Full Text]
Mukhopadhyay, N. K., Kim, J., Cinar, B., Ramachandran, A., Hager, M. H., Di Vizio, D., Adam, R. M., Rubin, M. A., Raychaudhuri, P., De Benedetti, A., Freeman, M. R.
(2009). Heterogeneous Nuclear Ribonucleoprotein K Is a Novel Regulator of Androgen Receptor Translation. Cancer Res.
69: 2210-2218
[Abstract][Full Text]
Boorjian, S. A, Heemers, H. V, Frank, I., Farmer, S. A, Schmidt, L. J, Sebo, T. J, Tindall, D. J
(2009). Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder. Endocr Relat Cancer
16: 123-137
[Abstract][Full Text]
McDonald, R., Roland, M.
(2009). Pay for Performance in Primary Care in England and California: Comparison of Unintended Consequences. Ann Fam Med
7: 121-127
[Abstract][Full Text]
Wang, G., Wang, J., Sadar, M. D.
(2008). Crosstalk between the Androgen Receptor and {beta}-Catenin in Castrate-Resistant Prostate Cancer. Cancer Res.
68: 9918-9927
[Abstract][Full Text]
Zhang, H., Muders, M. H., Li, J., Rinaldo, F., Tindall, D. J., Datta, K.
(2008). Loss of NKX3.1 Favors Vascular Endothelial Growth Factor-C Expression in Prostate Cancer. Cancer Res.
68: 8770-8778
[Abstract][Full Text]
Li, H., Xu, L. L., Masuda, K., Raymundo, E., McLeod, D. G., Dobi, A., Srivastava, S.
(2008). A Feedback Loop between the Androgen Receptor and a NEDD4-binding Protein, PMEPA1, in Prostate Cancer Cells. J. Biol. Chem.
283: 28988-28995
[Abstract][Full Text]
Seaton, A., Scullin, P., Maxwell, P. J., Wilson, C., Pettigrew, J., Gallagher, R., O'Sullivan, J. M., Johnston, P. G., Waugh, D. J. J.
(2008). Interleukin-8 signaling promotes androgen-independent proliferation of prostate cancer cells via induction of androgen receptor expression and activation. Carcinogenesis
29: 1148-1156
[Abstract][Full Text]
Nabhan, C.
(2008). Is Chemotherapy the Standard for Asymptomatic Androgen-Independent Prostate Cancer?. JCO
26: 2413-2414
[Full Text]
Sanders, T., Harrison, S., Checkland, K.
(2008). Evidence-based medicine and patient choice: the case of heart failure care. J Health Serv Res Policy
13: 103-108
[Abstract][Full Text]
Hara, T., Miyazaki, H., Lee, A., Tran, C. P., Reiter, R. E.
(2008). Androgen Receptor and Invasion in Prostate Cancer. Cancer Res.
68: 1128-1135
[Abstract][Full Text]
Schayowitz, A., Sabnis, G., Njar, V. C.O., Brodie, A. M.H.
(2008). Synergistic effect of a novel antiandrogen, VN/124-1, and signal transduction inhibitors in prostate cancer progression to hormone independence in vitro. Molecular Cancer Therapeutics
7: 121-132
[Abstract][Full Text]
Heemers, H. V., Tindall, D. J.
(2007). Androgen Receptor (AR) Coregulators: A Diversity of Functions Converging on and Regulating the AR Transcriptional Complex. Endocr. Rev.
28: 778-808
[Abstract][Full Text]
Dehm, S. M., Tindall, D. J.
(2007). Androgen Receptor Structural and Functional Elements: Role and Regulation in Prostate Cancer. Mol. Endocrinol.
21: 2855-2863
[Abstract][Full Text]
Heemers, H. V., Regan, K. M., Dehm, S. M., Tindall, D. J.
(2007). Androgen Induction of the Androgen Receptor Coactivator Four and a Half LIM Domain Protein-2: Evidence for a Role for Serum Response Factor in Prostate Cancer. Cancer Res.
67: 10592-10599
[Abstract][Full Text]
Reiner, T., de las Pozas, A., Parrondo, R., Perez-Stable, C.
(2007). Progression of Prostate Cancer from a Subset of p63-Positive Basal Epithelial Cells in FG/Tag Transgenic Mice. Mol Cancer Res
5: 1171-1179
[Abstract][Full Text]
Dehm, S. M., Regan, K. M., Schmidt, L. J., Tindall, D. J.
(2007). Selective Role of an NH2-Terminal WxxLF Motif for Aberrant Androgen Receptor Activation in Androgen Depletion Independent Prostate Cancer Cells. Cancer Res.
67: 10067-10077
[Abstract][Full Text]
Jiao, J., Wang, S., Qiao, R., Vivanco, I., Watson, P. A., Sawyers, C. L., Wu, H.
(2007). Murine Cell Lines Derived from Pten Null Prostate Cancer Show the Critical Role of PTEN in Hormone Refractory Prostate Cancer Development. Cancer Res.
67: 6083-6091
[Abstract][Full Text]
McDonald, R., Harrison, S., Checkland, K., Campbell, S. M, Roland, M.
(2007). Impact of financial incentives on clinical autonomy and internal motivation in primary care: ethnographic study. BMJ
334: 1357-1357
[Abstract][Full Text]
Tamura, K., Furihata, M., Tsunoda, T., Ashida, S., Takata, R., Obara, W., Yoshioka, H., Daigo, Y., Nasu, Y., Kumon, H., Konaka, H., Namiki, M., Tozawa, K., Kohri, K., Tanji, N., Yokoyama, M., Shimazui, T., Akaza, H., Mizutani, Y., Miki, T., Fujioka, T., Shuin, T., Nakamura, Y., Nakagawa, H.
(2007). Molecular Features of Hormone-Refractory Prostate Cancer Cells by Genome-Wide Gene Expression Profiles. Cancer Res.
67: 5117-5125
[Abstract][Full Text]
Yang, C.-C., Wang, Y.-C., Wei, S., Lin, L.-F., Chen, C.-S., Lee, C.-C., Lin, C.-C., Chen, C.-S.
(2007). Peroxisome Proliferator-Activated Receptor {gamma}-Independent Suppression of Androgen Receptor Expression by Troglitazone Mechanism and Pharmacologic Exploitation. Cancer Res.
67: 3229-3238
[Abstract][Full Text]
Heemers, H. V., Sebo, T. J., Debes, J. D., Regan, K. M., Raclaw, K. A., Murphy, L. M., Hobisch, A., Culig, Z., Tindall, D. J.
(2007). Androgen Deprivation Increases p300 Expression in Prostate Cancer Cells. Cancer Res.
67: 3422-3430
[Abstract][Full Text]
Walczak, J. R., Carducci, M. A.
(2007). Prostate Cancer: A Practical Approach to Current Management of Recurrent Disease. Mayo Clin Proc.
82: 243-249
[Abstract][Full Text]
Bonaccorsi, L., Nosi, D., Muratori, M., Formigli, L., Forti, G., Baldi, E.
(2007). Altered endocytosis of epidermal growth factor receptor in androgen receptor positive prostate cancer cell lines. J Mol Endocrinol
38: 51-66
[Abstract][Full Text]
Jia, L., Shen, H. C., Wantroba, M., Khalid, O., Liang, G., Wang, Q., Gentzschein, E., Pinski, J. K., Stanczyk, F. Z., Jones, P. A., Coetzee, G. A.
(2006). Locus-wide chromatin remodeling and enhanced androgen receptor-mediated transcription in recurrent prostate tumor cells.. Mol. Cell. Biol.
26: 7331-7341
[Abstract][Full Text]
Gao, H., Ouyang, X., Banach-Petrosky, W. A., Shen, M. M., Abate-Shen, C.
(2006). Emergence of Androgen Independence at Early Stages of Prostate Cancer Progression in Nkx3.1; Pten Mice. Cancer Res.
66: 7929-7933
[Abstract][Full Text]
Husbeck, B., Bhattacharyya, R. S., Feldman, D., Knox, S. J.
(2006). Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action.. Molecular Cancer Therapeutics
5: 2078-2085
[Abstract][Full Text]
Rosenfeld, M. G., Lunyak, V. V., Glass, C. K.
(2006). Sensors and signals: a coactivator/corepressor/epigenetic code for integrating signal-dependent programs of transcriptional response. Genes Dev.
20: 1405-1428
[Abstract][Full Text]
Wallner, L., Dai, J., Escara-Wilke, J., Zhang, J., Yao, Z., Lu, Y., Trikha, M., Nemeth, J. A., Zaki, M. H., Keller, E. T.
(2006). Inhibition of Interleukin-6 with CNTO328, an Anti-Interleukin-6 Monoclonal Antibody, Inhibits Conversion of Androgen-Dependent Prostate Cancer to an Androgen-Independent Phenotype in Orchiectomized Mice.. Cancer Res.
66: 3087-3095
[Abstract][Full Text]
Pienta, K. J., Bradley, D.
(2006). Mechanisms underlying the development of androgen-independent prostate cancer.. Clin. Cancer Res.
12: 1665-1671
[Full Text]
Gleave, M., Kelly, W. K.
(2005). High-Risk Localized Prostate Cancer: A Case for Early Chemotherapy. JCO
23: 8186-8191
[Abstract][Full Text]
Bhandari, M. S., Crook, J., Hussain, M.
(2005). Should Intermittent Androgen Deprivation Be Used in Routine Clinical Practice?. JCO
23: 8212-8218
[Abstract][Full Text]
Pienta, K. J., Smith, D. C.
(2005). Advances in Prostate Cancer Chemotherapy: A New Era Begins. CA Cancer J Clin
55: 300-318
[Abstract][Full Text]
Suriano, R., Ghosh, S. K., Ashok, B. T., Mittelman, A., Chen, Y., Banerjee, A., Tiwari, R. K.
(2005). Differences in Glycosylation Patterns of Heat Shock Protein, gp96: Implications for Prostate Cancer Prevention. Cancer Res.
65: 6466-6475
[Abstract][Full Text]
Stewart, J. R., O'Brian, C. A.
(2005). Protein kinase C-{alpha} mediates epidermal growth factor receptor transactivation in human prostate cancer cells. Molecular Cancer Therapeutics
4: 726-732
[Abstract][Full Text]